JSAM
VKTX icon

J. Safra Asset Management’s Viking Therapeutics VKTX Stock Holding History

J. Safra Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.74K Sell
224
-48
-18% -$1.55K ﹤0.01% 418
2026
Q1 		$8.85K Buy
272
+170
+167% +$5.46K ﹤0.01% 384
2025
Q4 		$3.59K Sell
102
-4
-4% -$142 ﹤0.01% 474
2025
Q3 		$2.79K Buy
106
+36
+51% +$1.07K ﹤0.01% 359
2025
Q2 		$1.85K Buy
+70
New +$1.84K ﹤0.01% 352

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

J. Safra Asset Management's VKTX Position: Q2 2026 in Review

J. Safra Asset Management reduced its Viking Therapeutics (VKTX) stake by 18% in Q2 2026, selling an estimated $1.55K and leaving 224 shares worth $8.74K. The position accounts for ﹤0.01% of the portfolio, ranked #418.

J. Safra Asset Management first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.85K in Q1 2026. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • J. Safra Asset Management held 224 shares of Viking Therapeutics worth $8.74K as of Q2 2026.
  • J. Safra Asset Management sold 48 Viking Therapeutics shares in Q2 2026, an estimated $1.55K.
  • Viking Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q2 2026, its #418 holding.
  • J. Safra Asset Management first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • J. Safra Asset Management's Viking Therapeutics position peaked at $8.85K in Q1 2026.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on J. Safra Asset Management's 13F filing for Q2 2026, filed 6 Aug 2026.